CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade.Frontiers in oncology · 2021
   Review
2. TIM-3, a promising target for cancer immunotherapy.OncoTargets and therapy · 2018
   Review
3. Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer.Molecular and clinical oncology · 2017
   Article
4. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.Medical science monitor : international medical journal of experimental and clinical research · 2017
   Article

Corrections and comments

• Erratum for
  Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.